Tradestie Institutional Equity Comparison Engine
ARDX vs NUVB โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ARDX Overall Edge
ARDX Captures Institutional Edge (4โ0 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Ardelyx, Inc. (ARDX) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, ARDX trades at 18.9x Forward P/E with -7.7% operating margin (+15.7% YoY revenue) versus NUVB at N/M Forward P/E and -61.2% operating margin (+242.6% YoY). In options structure, ARDX sits in BREAKDOWN (14th %ile IV; Dealer Gamma Walls on Pro) against NUVB sits in BREAKDOWN (26th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
ARDX
ARDX 18.9x vs NUVB N/M Fwd P/E
Growth & Margin Winner
ARDX
Op Margin -7.7% vs -61.2% ยท YoY +15.7% vs +242.6%
Momentum & Technical Winner
ARDX
1Y -46.3% vs -46.9% ยท 52W Pos 3% vs 2%
Options & Structure Winner
ARDX
BREAKDOWN (14th %ile IV) vs BREAKDOWN (26th %ile IV)
ARDX
NASDAQ
Ardelyx, Inc.
Pharmaceutical Preparations
$2.99
-2.29% 1D
Market Cap
$769.2M
1M Return
-6.56%
1Y Return
-46.32%
Forward P/E
18.9x
Unified AI Score
57.7 / 100
HOLD
Tech 43.0
Fund 54.0
Flow 70.0
Mom 54.0
NUVB
NYSE
Nuvation Bio Inc.
Pharmaceutical Preparations
$3.80
-0.26% 1D
Market Cap
$1.3B
1M Return
-19.15%
1Y Return
-46.85%
Forward P/E
N/M
Unified AI Score
61.0 / 100
BUY
Tech 53.0
Fund 61.0
Flow 67.0
Mom 64.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
ARDX -46.32%
NUVB -46.85%
Spread: +0.53 pp (ARDX Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | ARDX Revenue | NUVB Revenue | ARDX Op. Margin | NUVB Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $0M | N/A | -3488.6% | N/A | ARDX |
| FY2019 | $10M | N/A | -1728.1% | N/A | ARDX |
| FY2020 | $10M | N/A | -1199.0% | N/A | ARDX |
| FY2021 | $10M | N/A | -1528.6% | N/A | ARDX |
| FY2022 | $50M | N/A | -122.2% | N/A | ARDX |
| FY2023 | $120M | N/A | -50.8% | N/A | ARDX |
| FY2024 | $330M | $10M | -8.4% | -7527.3% | ARDX |
| FY2025 | $410M | $60M | -10.1% | -338.7% | ARDX |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ARDX | NUVB | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $769.2M | $1.3B | Larger Scale | NUVB |
| Trailing P/E Ratio Valuation | 52.1x | N/M | Lower Multiple | ARDX |
| Forward P/E Ratio Valuation | 18.9x | N/M | Lower Multiple | ARDX |
| Revenue Growth (YoY) Growth | +15.7% | +242.6% | Higher Growth | NUVB |
| Operating Margin (TTM) Profitability | -7.7% | -61.2% | Higher Margin | ARDX |
| Net Profit Margin Profitability | -11.8% | -67.4% | Higher Margin | ARDX |
| Return on Equity (ROE) Capital Efficiency | -34.8% | -49.1% | Higher ROE | ARDX |
| 52-Week Range Position Momentum | 3% ($3โ$8) | 2% ($4โ$10) | Stronger Trend | ARDX |
| Beta / 30D Volatility Risk Regime | 0.93ฮฒ ยท 56% Vol | 1.52ฮฒ ยท 55% Vol | Lower Realized Risk | NUVB |
| Unified Institutional Score Composite Signal | 57.7 / 100 (HOLD) | 61.0 / 100 (BUY) | Higher Composite | NUVB |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full ARDX vs NUVB Buy Guide
ARDX
BREAKDOWN
140d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
14th %ile
IV Regime
Compressed (<25th %ile)
NUVB
BREAKDOWN
105d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
26th %ile
IV Regime
Balanced (25thโ60th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither ARDX nor NUVB registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.